Ascorbate promotes the cellular accumulation of doxorubicin and reverses the multidrug resistance in breast cancer cells by inducing ROS-dependent ATP depletion

References

• DeSantis CE, Ma J, Goding Sauer A, et al. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 2017;67(6):439–448.
   PubMed Web of Science ®Google Scholar
• Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–289.
   PubMed Web of Science ®Google Scholar
• Doherty MK, Morris PG. Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy. Int J Women Health. 2015;7:47–58.
   PubMed Web of Science ®Google Scholar
• Banerjee K, Basu S, Das S, et al. Induction of intrinsic and extrinsic apoptosis through oxidative stress in drug–resistant cancer by a newly synthesized Schiff base copper chelate. Free Radic Res. 2016;50(4):426–446.
   PubMed Web of Science ®Google Scholar
• Cao X, Luo J, Gong T, et al. Coencapsulated doxorubicin and bromotetrandrine lipid nanoemulsions in reversing multidrug resistance in breast cancer in vitro and in vivo. Mol Pharm. 2015;12(1):274–286.
   PubMed Web of Science ®Google Scholar
• Hu Y, Guo R, Wei J, et al. Effects of PI3K inhibitor NVP–BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells. Cell Death Dis. 2015;6:e2020.
   PubMed Web of Science ®Google Scholar
• Kartner N, Riordan JR, Ling V. Cell surface P–glycoprotein associated with multidrug resistance in mammalian cell lines. Science. 1983;221(4617):1285–1288.
   PubMed Web of Science ®Google Scholar
• Traxl A, Wanek T, Mairinger S, et al. Breast cancer resistance protein and P–glycoprotein influence in vivo disposition of 11C–Erlotinib. J Nucl Med. 2015;56(12):1930–1936.
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP–dependent transporters. Nat Rev Cancer. 2002;2(1):48–58.
   PubMed Web of Science ®Google Scholar
• Chen Z, Shi T, Zhang L, et al. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decade. Cancer Lett. 2016;370(1):153–164.
   PubMed Web of Science ®Google Scholar
• Silva R, Vilas-Boas V, Carmo H, et al. Modulation of P–glycoprotein efflux pump: induction and activation as a therapeutic strategy. Pharmacol Ther. 2015;149:1–123.
   PubMed Web of Science ®Google Scholar
• Wang J, Qu H, Jin L, et al. Pegylated phosphotidylethanolamine inhibiting P–glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells. J Pharm Sci. 2011;100(6):2267–2277.
   PubMed Web of Science ®Google Scholar
• Fong MY, Zhou W, Liu L, et al. Breast–cancer-secreted miR–122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat Cell Biol. 2015;17(2):183–194.
   PubMed Web of Science ®Google Scholar
• Annibaldi A, Widmann C. Glucose metabolism in cancer cells. Curr Opin Clin Nutr. 2010;13(4):466–470.
   PubMed Web of Science ®Google Scholar
• Ma E, Chen P, Wilkins HM, et al. Pharmacologic ascorbate induces neuroblastoma cell death by hydrogen peroxide mediated DNA damage and reduction in cancer cell glycolysis. Free Radic Biol Med. 2017;113:36–47.
   PubMed Web of Science ®Google Scholar
• Liu M, Zheng M, Xu H, et al. Anti-pulmonary fibrotic activity of salvianolic acid B was screened by a novel method based on the cyto–biophysical properties. Biochem Biophys Res Commun. 2015;468(1–2):214–220.
   PubMed Web of Science ®Google Scholar
• Li YC, Chen J, Liu YT, et al. Nanoscale quantification of the biophysical characterization of combretastatin A–4–treated tumor cells using atomic force microscopy. PLoS One. 2017;12(6):e0179115.
   PubMed Web of Science ®Google Scholar
• Pan ST, Li ZL, He ZX, et al. Molecular mechanisms for tumour resistance to chemotherapy. Clin Exp Pharmacol Physiol. 2016;43(8):723–737.
   PubMed Web of Science ®Google Scholar
• Evans MK, Tovmasyan A, Batinic-Haberle I, et al. Mn porphyrin in combination with ascorbate acts as a pro-oxidant and mediates caspase–independent cancer cell death. Free Radic Biol Med. 2014;68:302–314.
   PubMed Web of Science ®Google Scholar
• Doskey CM, Buranasudja V, Wagner BA, et al. Tumor cells have decreased ability to metabolize H2O2: implications for pharmacological ascorbate in cancer therapy. Redox Biol. 2016;10:274–284.
   PubMed Web of Science ®Google Scholar
• Tovmasyan A, Go Y-M, Jones D, et al. Redox proteomics of 4T1 breast cancer cell after treatment with MnTE–2–PyP 5+/Ascorbate system. Free Radic Biol Med. 2016;100:S112–S113.
   Web of Science ®Google Scholar
• Fukui M, Yamabe N, Choi HJ, et al. Mechanism of ascorbate–induced cell death in human pancreatic cancer cells: role of Bcl–2, Beclin 1 and autophagy. Planta Med. 2015;81(10):838–846.
   PubMed Web of Science ®Google Scholar
• Verrax J, Beck R, Dejeans N, et al. Redox-active quinones and ascorbate: an innovative cancer therapy that exploits the vulnerability of cancer cells to oxidative stress. Anticancer Agents Med Chem. 2011;11(2):213–221.
   PubMed Web of Science ®Google Scholar
• Hou GX, Liu PP, Zhang S, et al. Elimination of stem-like cancer cell side-population by auranofin through modulation of ROS and glycolysis. Cell Death Dis. 2018;9(2):89.
   PubMedGoogle Scholar
• Pacheco-Velázquez SC, Robledo-Cadena DX, Hernández-Reséndiz I, et al. Energy metabolism drugs block triple negative breast metastatic cancer cell phenotype. Mol Pharm. 2018;15(6):2151–2164.
   PubMedGoogle Scholar
• Schoenfeld JD, Sibenaller ZA, Mapuskar KA, et al. Redox active metals and H2O2 mediate the increased efficacy of pharmacological ascorbate in combination with gemcitabine or radiation in pre-clinical sarcoma models. Redox Biol. 2018;14:417–422.
   PubMed Web of Science ®Google Scholar
• Rouleau L, Antony AN, Bisetto S, et al. Synergistic effects of ascorbate and sorafenib in hepatocellular carcinoma: new insights into ascorbate cytotoxicity. Free Radic Biol Med. 2016;95:308–322.
   PubMed Web of Science ®Google Scholar
• Kim TH, Shin YJ, Won AJ, et al. Resveratrol enhances chemosensitivity of doxorubicin in multidrug–resistant human breast cancer cells via increased cellular influx of doxorubicin. Biochim Biophys Acta. 2014;1840(1):615–625.
   PubMed Web of Science ®Google Scholar
• Chen T, Wang C, Liu Q, et al. Dasatinib reverses the multidrug resistance of breast cancer MCF–7 cells to doxorubicin by downregulating P–gp expression via inhibiting the activation of ERK signaling pathway. Cancer Biol Ther. 2015;16(1):106–114.
   PubMed Web of Science ®Google Scholar
• Del Nagro C, Xiao Y, Rangell L, et al. Depletion of the central metabolite NAD leads to oncosis-mediated cell death. J Biol Chem. 2014;289(51):35182–35192.
   PubMed Web of Science ®Google Scholar